![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Objective: To assess the peak inspiratory flow rate (PIFR) and forced inspiratory vital capacity (FIVC) through the formoterol (Foradil) Aerolizer* in patients with mild, moderate and severe asthma.
* Foradil and Aerolizer are trade names of Novartis AG, Basel, Switzerland
Research design and methods: PIFR and FIVC were assessed in 33 adults and 32 children using a spirometer alone (baseline), a spirometer with an adaptor, and a spirometer with an adaptor and the Aerolizer inhaler (placebo loaded).
Results: Of adult patients using the Aerolizer inhaler, 73% had PIFR values of >100l/min and 91% had values of >60l/min. PIFR in adults was reduced from a mean baseline of 283l/min to 118l/min through the loaded Aerolizer inhaler. Similarly, 75% of children using the Aerolizer inhaler had PIFR values >80l/min and 91% had values of >60l/min. The mean PIFR in children was reduced from a baseline of 154l/min to 100l/min through the loaded Aerolizer inhaler. Only small mean decreases from baseline were observed in FIVC through the loaded Aerolizer inhaler: 8.4% in adults and 3.8% in children. FIVC values of >2.0 litre were achieved in 82% of adults, and 81% of children achieved FIVC values of >1.5 litre.
Conclusion: This study, albeit in a relatively small patient population, suggests that most children and adults with asthma can generate PIFRs of >60l/min and FIVCs of >1.5litre through the Aerolizer inhaler regardless of their disease severity. Such findings compare extremely favourably with other dry powder inhalers.
Notes
* Foradil and Aerolizer are trade names of Novartis AG, Basel, Switzerland